Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers

Thromb Haemost. 2005 Apr;93(4):794-5.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Biomarkers / blood
  • Blood Coagulation / drug effects
  • Cyclic N-Oxides / administration & dosage*
  • Cyclic N-Oxides / pharmacokinetics
  • Drug Therapy, Combination
  • Factor Xa Inhibitors
  • Humans
  • Male
  • Partial Thromboplastin Time
  • Platelet Aggregation / drug effects
  • Pyridines / administration & dosage*
  • Pyridines / pharmacokinetics
  • Tirofiban
  • Tyrosine / administration & dosage
  • Tyrosine / analogs & derivatives*
  • Tyrosine / pharmacokinetics

Substances

  • Biomarkers
  • Cyclic N-Oxides
  • Factor Xa Inhibitors
  • Pyridines
  • Tyrosine
  • Tirofiban
  • otamixaban